Subsequent Events (Details Narrative) - USD ($) |
3 Months Ended | ||
---|---|---|---|
Apr. 20, 2020 |
Mar. 31, 2020 |
Mar. 31, 2019 |
|
Payments for consulting | $ 98,223 | $ 140,029 | |
License Agreement [Member] | QSAM Therapeutics Inc [Member] | |||
Agreement term description | The License Agreement is for 20 years or until the expiration of the multiple patents covered under the license, and requires multiple milestone based payments including: $60,000 and other expense reimbursements within 60 days of signing, up to $150,000 as the Technology advances through multiple stages of clinical trials, and $1.5 million upon commercialization. IGL will also receive equity in QSAM equal to 5% of the company to be issued within 60 days of signing. Upon commercialization, IGL will receive an on-going royalty equal to 4.5% of Net Sales, as defined in the License Agreement, and up to 50% of any Sublicense Consideration received by QSAM, as defined in the License Agreement. | ||
Other expense reimbursements | $ 60,000 | ||
Payments for commercialization | $ 1,500,000 | ||
Equity ownership percentage | 5.00% | ||
Royalty percentage | 4.50% | ||
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member] | |||
Advances for technology | $ 150,000 | ||
Royalty percentage | 50.00% | ||
License Agreement [Member] | IGL Pharma Inc [Member] | |||
Equity ownership percentage | 25.00% | ||
Two-Year Consulting and Confidentiality Agreement [Member] | IGL Pharma Inc [Member] | |||
Payments for consulting | $ 8,500 |
X | ||||||||||
- Definition Advances for technology. No definition available.
|
X | ||||||||||
- Definition Agreement term description. No definition available.
|
X | ||||||||||
- Definition Royalty percentage. No definition available.
|
X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The total expense recognized in the period for promotion, public relations, and brand or product advertising. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|